Form 4: Avanos Medical Interim CEO Michael Greiner Acquires 10,000 Shares Through Restricted Stock Units

Sentiment:

SEC Form 4 Filing


Avanos Medical's Interim CEO, Michael Greiner, acquired 10,000 shares of common stock through the vesting of time-based restricted stock units.

Summary

  • Michael Greiner, the Interim CEO of Avanos Medical, acquired 10,000 shares of common stock on December 3, 2024.
  • The shares were acquired through the vesting of time-based restricted stock units (TRSUs) granted under the company's 2021 Long Term Incentive Plan.
  • These TRSUs will vest on December 3, 2025, unless Mr. Greiner's employment is terminated without cause before that date, in which case they will vest immediately.
  • Following this transaction, Mr. Greiner now beneficially owns 200,898 shares of Avanos Medical common stock.

Sentiment

Score: 7

Explanation: The document reflects a positive sentiment as it shows the CEO's increased stake in the company, which is generally viewed favorably by investors. The transaction is part of a standard compensation plan.

Positives

  • The acquisition of shares by the Interim CEO demonstrates confidence in the company's future.
  • The vesting of restricted stock units aligns the CEO's interests with those of the shareholders.

Future Outlook

The restricted stock units will vest on December 3, 2025, contingent on continued employment, unless terminated without cause.

Industry Context

This is a standard practice for executive compensation, aligning management's interests with shareholders through equity ownership.

Comparison to Industry Standards

  • The use of restricted stock units is a common practice in executive compensation across various industries, including medical technology.
  • Many companies in the medical device sector use similar long-term incentive plans to retain and motivate key executives.
  • The vesting period of one year is fairly standard for these types of awards.

Stakeholder Impact

  • The increased share ownership by the CEO may positively impact shareholder confidence.
  • The vesting of restricted stock units aligns the CEO's interests with those of the shareholders.

Key Dates

DateDescription
12/03/2024Date of the transaction where Michael Greiner acquired 10,000 shares.
12/03/2025Vesting date for the restricted stock units, unless employment is terminated without cause.
12/05/2024Date the form was signed.

Keywords

Avanos Medical, Michael Greiner, restricted stock units, share acquisition, insider trading, executive compensation, long term incentive plan

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.